ArticleERJ open research2023
Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics.
Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Longer Asthma Duration Is Associated With Elevated Non-T2 Sputum Biomarkers and Reduced T2 Inflammation in Severe Asthma.Allergy · 2026Observational
- Molecular Phenotyping Based on Blood Transcriptome-Associated Clusters in Asthma: Findings From Two Korean Asthma Cohorts.Allergy, asthma & immunology research · 2026Article
- Circulating 1-Methylnicotinamide Predicts Dupilumab Response in Adult Asthma: A Prediction Model.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Unsupervised Machine-Learning-Based Endotype Discovery Using Iterative Resampling in Dupilumab-Treated Patients.International journal of molecular sciences · 2026Article
- Effectiveness of low-dose mepolizumab in refractory eosinophilic granulomatosis with polyangiitis: systemic steroid use and remission.The Korean journal of internal medicine · 2026Observational
- Biologic Therapies and Quality of Life in Pediatric Patients with Asthma: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Impact of Biologics on Nasal Symptoms in Severe Asthmatics: Findings From the PRISM Study.Allergy, asthma & immunology research · 2025Article
- Siglec-8 as a Biomarker for Predicting Anti-IL-5 Response in Severe Asthma.Allergy, asthma & immunology research · 2025Article
- Biomarkers of type 2 inflammation as predictors of response to biologics for severe eosinophilic asthma.ERJ open research · 2025Article
- Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment.The World Allergy Organization journal · 2024Article
- Single-cell RNA sequencing reveals transcriptional changes in circulating immune cells from patients with severe asthma induced by biologics.Experimental & molecular medicine · 2024Observational
- Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study.The World Allergy Organization journal · 2024Article
- The Role of Exhaled Breath Condensate in Chronic Inflammatory and Neoplastic Diseases of the Respiratory Tract.International journal of molecular sciences · 2024Review
- Assessment of Treatment Response in Patients With Severe Asthma Using Visual and Quantitative Analysis of Chest CT.Korean journal of radiology · 2024Article
- Article
- Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein-protein interaction analyses.Respiratory research · 2023Article
- A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study.The World Allergy Organization journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
Abstract
Severe asthma represents an important clinical unmet need despite the introduction of biologic agents. Although advanced omics technologies have aided researchers in identifying clinically relevant molecular pathways, there is a lack of an integrated omics approach in severe asthma particularly in terms of its evolution over time. The collaborative Korea-UK research project Precision Medicine Intervention in Severe Asthma (PRISM) was launched in 2020 with the aim of identifying molecular phenotypes of severe asthma by analysing multi-omics data encompassing genomics, epigenomics, transcriptomics, proteomics, metagenomics and metabolomics. PRISM is a prospective, observational, multicentre study involving patients with severe asthma attending severe asthma clinics in Korea and the UK. Data including patient demographics, inflammatory phenotype, medication, lung function and control status of asthma will be collected along with biological samples (blood, sputum, urine, nasal epithelial cells and exhaled breath condensate) for omics analyses. Follow-up evaluations will be performed at baseline, 1 month, 4-6 months and 10-12 months to assess the stability of phenotype and treatment responses for those patients who have newly begun biologic therapy. Standalone and integrated omics data will be generated from the patient samples at each visit, paired with clinical information. By analysing these data, we will identify the molecular pathways that drive lung function, asthma control status, acute exacerbations and the requirement for daily oral corticosteroids, and that are involved in the therapeutic response to biological therapy. PRISM will establish a large multi-omics dataset of severe asthma to identify potential key pathophysiological pathways of severe asthma.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.